Opportunity Information: Apply for RFA DA 23 062
The NIH National Institute on Drug Abuse (NIDA) is offering the R34 funding opportunity called "NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (Clinical Trial Optional)" under Funding Opportunity Number RFA-DA-23-062 (CFDA 93.279). This announcement sits within NIDA's larger Racial Equity Initiative (REI), which is described as a multi-year and multi-pronged effort aimed at eliminating racial inequities across NIDA's internal environment, the broader scientific workforce, and the research NIDA funds. In practical terms, this FOA is designed to move the field toward more equitable HIV outcomes by supporting early-stage research that can be tested, refined, and positioned for larger-scale studies and interventions later.
The core goal of this FOA is to fund pilot or feasibility projects that examine and address HIV-related health disparities that arise where HIV and substance use overlap, specifically among underserved racial and/or ethnic populations experiencing persistent HIV disparities. Rather than focusing only on individual behavior change, the emphasis is on upstream drivers of inequity: structural factors (such as access barriers, stigma embedded in systems, or broader social determinants), organizational practices (how clinics, service providers, justice settings, schools, or community programs operate), policies (local, state, or institutional rules that shape who gets care and how), and other social, cultural, and contextual influences that produce unequal HIV outcomes in the context of substance use. The intent is to help applicants generate credible preliminary evidence, test novel approaches, and work through implementation realities in real-world settings where disparities are produced and maintained.
A notable feature of the announcement is its explicit encouragement of research that uses an intersectional lens. NIDA is signaling that strong applications will often consider how multiple dimensions of identity and social position interact, including race and ethnicity, but also gender, sexual orientation, and gender identity, along with the social systems people navigate. In other words, the FOA supports approaches that do not treat communities as monolithic and that recognize how overlapping forms of marginalization can shape HIV risk, access to prevention and treatment, and outcomes for people who use substances. This can include projects that design or adapt interventions, test service delivery models, or evaluate organizational or policy changes intended to reduce inequities at the HIV-substance use intersection.
This is an R34 mechanism, meaning it is generally meant for developmental, pilot, or feasibility work rather than large definitive trials. The FOA is labeled "Clinical Trial Optional," which means applicants may propose a clinical trial if it fits the aims, but a clinical trial is not required. The focus remains on generating early evidence and practical learning that can support later, larger effectiveness or implementation studies, particularly those that address inequities embedded in systems and contexts.
Eligibility is broad and includes a wide range of public and private entities. Eligible applicants listed include state governments, county governments, city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, public housing authorities/Indian housing authorities, Native American tribal organizations (other than federally recognized tribal governments), nonprofits with and without 501(c)(3) status (other than institutions of higher education), for-profit organizations other than small businesses, small businesses, and other organizations. The FOA also explicitly highlights additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American tribal governments that are not federally recognized, and U.S. territories or possessions. These inclusions underscore the program's intent to support applicants embedded in, or closely partnered with, the communities and systems most affected by the disparities the FOA is trying to reduce.
There are also clear limitations related to foreign participation. While "foreign components" as defined in the NIH Grants Policy Statement are allowed, non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply as applicant organizations. In addition, non-domestic components of U.S. organizations are not eligible to apply. This effectively means the application must be led by an eligible U.S.-based applicant organization, though certain defined international elements may be permissible as part of the project under NIH policy.
From an administrative standpoint, the opportunity is categorized as a discretionary grant in the education and health activity area, administered by the National Institutes of Health. The original closing date listed is 2024-11-14. The award ceiling is shown as $450,000, indicating the maximum total award amount under the opportunity as presented in the source data. The announcement was created on 2022-10-03, reflecting when it entered the system. Overall, this FOA is best understood as a targeted, equity-driven pilot funding program intended to catalyze new, system-aware research approaches that can reduce HIV disparities tied to substance use in underserved racial and/or ethnic populations, with a strong preference for work that explicitly grapples with intersecting identities and the real structural conditions shaping health.Apply for RFA DA 23 062
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2022-10-03.
- Applicants must submit their applications by 2024-11-14. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1) What is this funding opportunity?
This is an NIH National Institute on Drug Abuse (NIDA) R34 funding opportunity titled "NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (Clinical Trial Optional)" under Funding Opportunity Number RFA-DA-23-062 (CFDA 93.279).
2) Which NIH institute is offering this grant?
The opportunity is offered by the NIH National Institute on Drug Abuse (NIDA).
3) What does REI mean in this announcement?
REI refers to NIDA's Racial Equity Initiative, described as a multi-year, multi-pronged effort to eliminate racial inequities across NIDA's internal environment, the broader scientific workforce, and the research NIDA funds.
4) What is the main purpose of this FOA?
The FOA is intended to fund pilot or feasibility projects that examine and address HIV-related health disparities where HIV and substance use overlap, specifically among underserved racial and/or ethnic populations experiencing persistent HIV disparities.
5) What type of projects is NIDA trying to support with this R34?
NIDA is supporting early-stage, developmental research that can be tested and refined and then positioned for larger-scale studies and interventions later. The intent includes generating credible preliminary evidence and learning what works in real-world settings.
6) Is this meant to fund large, definitive studies?
No. The R34 mechanism is generally meant for developmental, pilot, or feasibility work rather than large, definitive trials.
7) Are clinical trials required?
No. The FOA is labeled "Clinical Trial Optional," meaning a clinical trial may be proposed if it fits the aims, but it is not required.
8) If clinical trials are optional, what is the emphasis instead?
The emphasis is on producing early evidence and practical learning that can support later, larger effectiveness or implementation studies, particularly studies that address inequities embedded in systems and contexts affecting HIV outcomes in the presence of substance use.
9) What populations is this FOA focused on?
The FOA focuses on underserved racial and/or ethnic populations experiencing persistent HIV disparities, specifically in the context where HIV and substance use overlap.
10) What does the FOA mean by focusing on "upstream drivers of inequity"?
Rather than focusing only on individual behavior change, this FOA emphasizes upstream drivers such as structural factors (for example, access barriers or stigma embedded in systems), organizational practices (how clinics, service providers, justice settings, schools, or community programs operate), policies (local, state, or institutional rules that shape care access and delivery), and other social, cultural, and contextual influences that produce unequal HIV outcomes.
11) What kinds of settings or systems might be relevant to a project?
Examples named in the opportunity include clinics, service providers, justice settings, schools, and community programs. More broadly, any real-world setting where disparities are produced and maintained may be relevant based on the FOA's focus.
12) Does NIDA want projects that only focus on individual-level interventions?
The FOA explicitly emphasizes upstream drivers of inequity, indicating interest in structural, organizational, policy, and contextual approaches rather than an exclusive focus on individual behavior change.
13) What does an "intersectional lens" mean in this FOA?
NIDA is encouraging applicants to consider how multiple dimensions of identity and social position interact. In addition to race and ethnicity, this can include gender, sexual orientation, and gender identity, as well as the social systems people navigate.
14) Why is intersectionality highlighted as important here?
The FOA signals that strong applications will often recognize that communities are not monolithic and that overlapping forms of marginalization can shape HIV risk, access to prevention and treatment, and health outcomes for people who use substances.
15) What types of approaches could be supported under this FOA?
Based on the description, supported approaches may include designing or adapting interventions, testing service delivery models, or evaluating organizational or policy changes intended to reduce inequities at the HIV-substance use intersection.
16) Who is eligible to apply?
Eligibility is broad and includes many public and private entities, including state governments, county governments, city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, public housing authorities/Indian housing authorities, Native American tribal organizations (other than federally recognized tribal governments), nonprofits with and without 501(c)(3) status (other than institutions of higher education), for-profit organizations other than small businesses, small businesses, and other organizations.
17) Are minority-serving institutions explicitly included?
Yes. The FOA explicitly highlights eligibility for institutions and organization types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
18) Are faith-based and community-based organizations eligible?
Yes. The FOA explicitly highlights faith-based or community-based organizations as eligible applicant types.
19) Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are explicitly listed among eligible applicant types.
20) Can federal agencies apply?
Yes. The FOA explicitly mentions eligible federal agencies as included among eligible applicants.
21) Can non-federally recognized tribes participate?
The FOA lists "Indian/Native American tribal governments that are not federally recognized" among additional eligible applicant types, and it also lists "Native American tribal organizations (other than federally recognized tribal governments)" among eligible applicants.
22) Can foreign organizations apply as the applicant?
No. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply as applicant organizations.
23) Can a U.S. organization submit an application led by a non-U.S. component?
No. Non-domestic components of U.S. organizations are not eligible to apply, as described in the opportunity summary.
24) Are any international activities allowed at all?
Yes, with limits. "Foreign components" as defined in the NIH Grants Policy Statement are allowed, even though foreign entities cannot apply as the applicant organization.
25) What is the activity area and grant type for this opportunity?
The opportunity is categorized as a discretionary grant in the education and health activity area, administered by the National Institutes of Health.
26) What is the application deadline listed in the provided information?
The original closing date listed is 2024-11-14.
27) What is the maximum award amount (award ceiling) shown?
The award ceiling is shown as $450,000 (the maximum total award amount presented in the source data provided).
28) When was this announcement created?
The announcement was created on 2022-10-03, reflecting when it entered the system.
29) How does this FOA fit into NIDA's broader goals?
This FOA sits within NIDA's Racial Equity Initiative and is intended to move the field toward more equitable HIV outcomes by catalyzing new, system-aware research approaches that address HIV disparities tied to substance use in underserved racial and/or ethnic populations.
30) What kind of progress is NIDA expecting from funded projects?
The FOA is designed to support early-stage research that can be tested, refined, and positioned for larger-scale studies later. It emphasizes generating credible preliminary evidence and working through practical implementation realities in the settings where disparities are produced and maintained.
Browse more opportunities from the same category: Education, Health
Next opportunity: Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
Previous opportunity: Genetic Tools for Understanding Rickettsial and Related Infections (R61/R33 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 23 062
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 23 062) also looked into and applied for these:
| Funding Opportunity |
|---|
| Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) Apply for RFA CA 22 056 Funding Number: RFA CA 22 056 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) Apply for PAR 23 034 Funding Number: PAR 23 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01 Clinical Trial Not Allowed) Apply for RFA DE 23 013 Funding Number: RFA DE 23 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) Apply for RFA DA 24 007 Funding Number: RFA DA 24 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) Apply for PAR 23 021 Funding Number: PAR 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional) Apply for PAR 22 249 Funding Number: PAR 22 249 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed) Apply for PAR 22 239 Funding Number: PAR 22 239 Agency: National Institutes of Health Category: Education, Health Funding Amount: $375,000 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed) Apply for RFA CA 23 018 Funding Number: RFA CA 23 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) Apply for PAR 23 041 Funding Number: PAR 23 041 Agency: National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit (U24 Clinical Trial Not Allowed) Apply for RFA CA 23 019 Funding Number: RFA CA 23 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) Apply for RFA DA 24 003 Funding Number: RFA DA 24 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed) Apply for RFA DA 24 004 Funding Number: RFA DA 24 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) Apply for RFA DA 23 036 Funding Number: RFA DA 23 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Transformative Educational Advancement and Mentoring Network (TEAM) (R25 Clinical Trial Not Allowed) Apply for RFA CA 23 013 Funding Number: RFA CA 23 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional) Apply for RFA DA 23 059 Funding Number: RFA DA 23 059 Agency: National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional) Apply for RFA DA 23 060 Funding Number: RFA DA 23 060 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) Apply for RFA DA 24 002 Funding Number: RFA DA 24 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required) Apply for RFA CA 23 020 Funding Number: RFA CA 23 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1 Clinical Trial Required) Apply for RFA CA 23 021 Funding Number: RFA CA 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required) Apply for RFA CA 23 022 Funding Number: RFA CA 23 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 23 062", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.